Clinical trial · Interventional
The Effect of Andrographis Paniculata (AP) on Palliative Management of Advanced Esophageal Cancer
NCT04196075CI-TRIAL-00054944APcompletedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective cohort study on the effect of Andrographis Paniculata (AP) on palliative management of patients with advanced or metastatic esophageal cancer. A total of 30 patients with locally advanced or metastatic squamous esophageal cancer will be recruited for the trial.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Squamous Cell Carcinoma of Esophagus | Esophageal Squamous Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Andrographis Paniculata | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Andrographis Paniculata treatment
- description
- Single lot of Andrographis paniculata (AP) concentrated granules (Andrographis Herba) will be manufactured by Nong's Company Limited under GMP standard
- interventionNames
- Drug: Andrographis Paniculata
Primary outcomes (1)
- measure
- Symptomatic relief and quality of life after AP
- timeFrame
- 4 months
- description
- Symptomatic relief of Dysphagia and quality of life after treatment Dysphagia measured by Dysphagia score Quality of Life measured by EORTC-QLQ-C30
Secondary outcomes (4)
- measure
- Difficulty to swallow
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Aged over 18 2. Locally advanced esophageal cancer with invasion or adherent to surrounding organs including trachea, recurrent laryngeal nerves and descending aorta; 3. Presence of distant metastasis; 4. Extensive lymph node metastasis to beyond surgical therapy Exclusion Criteria: 1. Patients who cannot receive palliative stenting for dysphagia or under other conventional treatment including chemotherapy or chemoradiotherapy 2. Patients who are not willing to receive Chinese herbal medicines 3. Patients who do not consent for the study
References
Publications (0)
Data not yet available
No reference posted for this study.